Menu
Not yet recruiting NCT06647277

Fecal MicrobiotaTransplant for the Treatment of Parkinson's Disease

Phase I Interventional Parkinson Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Fecal Microbiota Transplant.
Who it may be relevant to
Registry conditions: Parkinson Disease. Basic parameters: 18 years — 85 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

An Open-Label Phase I Clinical Trial of Vancomycin Followed by Fecal Microbiota Transplant for the Treatment of Parkinson's Disease

Overview

FMT may significantly improve quality of life and Parkinson Disease (PD) symptom severity measurements. We hypothesize that gut microbial dysbiosis is a major contributing factor in Parkinson's disease.

Detailed description

This is an open-label clinical trial to evaluate the Safety of fecal microbiota transplant following a 10 day treatment with Vancomycin in adult subjects with Parkinson's disease. Subjects in the study are required to meet with the study clinician on 11 occasions: two (2) visits for informed consent and baseline assessment, one (1) visit prior to FMT for colonoscopy instructions and exam, one (1) visit for the fecal microbiota transplant procedure by colonoscopy at an outpatient surgical center, seven (7) visits for post-FMT assessment. There are also daily phone calls in the week following the FMT, and weekly phone call visits (during weeks in which there is not a physical visit) to check up on how the subject is doing, any change in medications, side effects, and answer any questions.

Interventions

  • Combination product Fecal Microbiota Transplant
    Fecal Microbiota Transplant

Primary outcome measures

  • Parkinson's disease symptoms [Time frame: 6.5 months for each subject]
Secondary outcome measures (1)
  • Alterations in Subject microbiome from baseline [Time frame: 6.5 months for each subject]

Eligibility criteria

Inclusion criteria

  • Individuals diagnosed with PD

Exclusion criteria

  • Non-PD individuals

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Supportive care

Study locations

United States · 1 center
  • Sabine Hazan — Ventura

Identifiers

NCT: NCT06647277 · PRG-056

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗